US 7,544,371 B2
	Drug delivery systems
Jay Kunzler, Canandaigua, N.Y. (US); and Joseph Salamone, Boca Raton, Fla. (US)
Assigned to Bausch + Lomb Incorporated, Rochester, N.Y. (US)
Filed on Dec. 20, 2005, as Appl. No. 11/311,983.
Prior Publication US 2007/0141115 A1, Jun. 21, 2007
Int. Cl. A61K 9/14 (2006.01); A61F 2/00 (2006.01)

U.S. Cl. 424—484  [424/427; 424/486]

10 Claims

1. A matrix controlled diffusion drug delivery system comprising a therapeutically effective amount of one or more pharmaceutically active agents entrapped in a polymerization product of a monomeric mixture comprising one or more silicone-containing monomers of the general formula: wherein x and y are independently integers from 0 to about 300; m and m′ are independently integers from 1 to about 6, R is independently a straight or branched, substituted or unsubstituted, C1-C30 alkyl group, a C1-C30 fluoroalkyl group, an ether or polyether containing group or a C1-C30 alkylamide group, R1, R2, R3, R4, R5, R6 and R7 are independently hydrogen, a straight or branched C1-C30 alkyl group, a C1-C30 fluoroalkyl group, a C1-C20 ester group, an alkyl ether, cycloalkyl ether, cycloalkylalkyl ether, cycloalkenyl ether, aryl ether, arylalkyl ether or polyether containing group, an ureido group, an amide group, an amine group, a substituted or unsubstituted C1-C30 alkoxy group, a substituted or unsubstituted C3-C30 cycloalkyl group, a substituted or unsubstituted C3-C30 cycloalkylalkyl group, a substituted or unsubstituted C3-C30 cycloalkenyl group, a substituted or unsubstituted C5-C30 aryl group, a substituted or unsubstituted C5-C30 arylalkyl group, a substituted or unsubstituted C5-C30 heteroaryl group, a substituted or unsubstituted C3-C30 heterocyclic ring, a substituted or unsubstituted C4-C30 heterocyclolalkyl group, a substituted or unsubstituted C6-C30 heteroarylalkyl group, fluorine, a vinyl group, a C5-C30 fluoroaryl group, or a hydroxyl group; X is independently a straight or branched C1-C30 alkyl group, a C1-C30 fluoroalkyl group, a substituted or unsubstituted C5-C30 arylalkyl group, a substituted or unsubstituted C1-C30 alkoxy group, an ether, polyether, sulfide, or amino containing group and Z and Z′ are independently a polymerizable ethylenically unsaturated organic radical, wherein the matrix controlled diffusion drug delivery system is sized and configured for back of the eye delivery.